On January 15, local time, Sino Biopharm (1177.HK) attended the 44th J.P. Morgan Healthcare Conference and gave a systematic presentation on the company's strategic M&A, technology platforms, and innovative pipeline, showcasing its steady pace of accelerating innovation and expansion to the global market.

On January 13, Sino Biopharm (1177.HK) announced that it will fully acquire Hangzhou Hygieia Pharmaceuticals Co., Ltd. (hereinafter referred to as "Hygieia"), a domestic innovative drug company in the small interfering RNA (siRNA) field, for a total price of RMB 1.2 billion.

On December 19, at the "2025 TVB Environmental, Social, and Governance (ESG) Awards Presentation Ceremony" held in Hong Kong, organized by TVB and co-organized by the Hong Kong Productivity Council, Sino Biopharmaceutical Limited (1177.HK) was honored with the "ESG Social Innovation Science and Technology Award" for its innovative practices in carbon neutrality strategy and climate risk governance.

On December 16, the "2025 Science and Technology + New Quality Productive Forces Summit", organized by the Hong Kong China Friendship Association, was held in Hong Kong.